Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 2003-2007

  Ritchie, Ellen K ^a,b   Feldman, Eric J ^a   Christos, Paul J ^b   Rohan, Sarah D ^a   Lagassa, Catherine B ^a   Ippoliti, Cindy ^a   Scandura, Joseph M ^a   Carlson, Karen ^a   Roboz, Gail J ^a  

^a New York Presbyterian Hospital ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute; Drug therapy; Induction chemotherapy methods; Leukemia; Myeloid; Treatment outcome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; CYTARABINE; GEMTUZUMAB OZOGAMICIN; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84879783893     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.762093     Document Type: Article

References (20)

1. Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 2010;28:586-595.
2. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia :A study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61-69.
3. Appelbaum F R, Gundacker H, Head D R, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
4. Kantarjian H, O ' Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 2006;106:1090-1098.
5. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476-479.
6. Chevallier P, Labopin M,Turlure P,et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients :A GOELAMS study. Leukemia 2011;25:939-944.
7. Cashen AF, Schiller GJ, O ' Donnell MR, et al. Phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556-561.
8. Thomas XG, Dmoszynska A, Wierzbowska A, et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J Clin Oncol 2011;29(Suppl.):Abstract 6504.
9. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473-7478.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France:IARC;2008.
11. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
12. Grimwade D. Impact of cytogenetics on clinical outcome in AML. In:Karp J, editor. Acute myelogenous leukemia. Totowa, NJ:Humana Press;2007. pp 177-192.
13. Roboz GJ, Wissa U, Ritchie EK, et al. Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leuk Res 2012;36:407-412.
14. Roboz GJ, Ritchie EK, Curcio T, et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008;113:2504-2511.
15. Karp JE, Flatten K, Feldman EJ, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia :A preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined wiThetoposide. Blood 2009;113:4841-4852.
16. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009;115:5746-5751.
17. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012;97:393-401.
18. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaBdependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008;111:2364-2373.
19. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012;119:6025-6031.
20. Decitabine with or without bortezomib in treating older patients with acute myeloid leukemia. 2011. Available from: Http://clinicaltrials. gov/show/NCT01420926